Vaccine Research and Development Recommendations for Advancing Pandemic and Seasonal Influenza Preparedness and Response

Webcast

Regulatory Science of Influenza Vaccine Research and Development

June 10, 2021

3:00 PM - 6:00 PM (ET)

Past

Agenda

About

The committee will continue its discussion on advancements in vaccine platform technologies and regulatory science driven by COVID-19. This meeting will center on regulatory considerations for development of novel influenza vaccines and bringing vaccines to market. Speakers will highlight global collaboration and equity as critical components of sustainable advancement.

Additional Information

Is it a Closed Session event?

Partially Closed

The following committee members were present at the closed sessions of the event

• Enriqueta Bond
• Maria Elena Bottazzi
• Annette Fox
• Rebecca Cox
• Florian Krammer
• Grace Lee
• Josh Sharfstein
• Milagritos Tapia

The following topics were discussed in the closed sessions:

• Debrief of Speaker Presentations
• Structure of Feature Meetings
• Next Steps

Date of posting of Closed Session Summary:

June 15, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Webcast

Manufacturing Science of Influenza Vaccine Research and Development

May 26, 2021

3:00 PM - 6:00 PM (ET)

Past

Agenda

Download the Agenda

About

The committee will discuss advancements in vaccine platform technologies and manufacturing science driven by COVID-19. This meeting will center on building manufacturing capacity for new vaccines. Speakers will highlight global collaboration and equity as critical components of sustainable advancement.

Additional Information

Is it a Closed Session event?

Partially Closed

The following committee members were present at the closed sessions of the event

• Enriqueta Bond
• Kanta Subbarao
• Maria Elena Bottazzi
• Florian Krammer
• Grace Lee
• Milagritos Tapia
• Joshua Sharfstein

The following topics were discussed in the closed sessions:

• Debrief of Speaker presentations
• Structure of Feature Meetings
• Next Steps

The following materials (written documents) were made available to the committee in the closed sessions:

Briefing Book

Date of posting of Closed Session Summary:

May 28, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Webcast

Priorities for Clinical Development of Vaccines for Influenza Preparedness

May 12, 2021

8:00 AM - 11:00 AM (ET)

Past

Agenda

Download the Agenda

About

The COVID-19 pandemic has facilitated rapid advancement of platform technologies for vaccine development. During this meeting, the committee will discuss the ways in which lessons from the clinical development of the COVID-19 vaccine can be leveraged to improve influenza vaccine research and development. The session will apply previous discussions about best practices in clinical science and emerging technologies to fit a global context as it pertains to seasonal, pandemic and universal influenza.

Additional Information

Is it a Closed Session event?

Partially Closed

The following committee members were present at the closed sessions of the event

• Enriqueta Bond
• Kanta Subbarao
• Annette Fox
• Maria Elena Bottazzi
• Rebecca Cox
• Florian Krammer
• Grace Lee
• Joshua Sharfstein

The following topics were discussed in the closed sessions:

• Debrief of Speaker presentations
• Structure of Feature Meetings
• Next Steps

The following materials (written documents) were made available to the committee in the closed sessions:

Briefing Book

Date of posting of Closed Session Summary:

May 17, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Webcast

Clinical Development of Vaccine Platforms for Influenza Preparedness

April 28, 2021

3:00 PM - 4:30 PM (ET)

Past

Agenda

Download the Agenda

About

The COVID-19 pandemic has facilitated rapid advancement of platform technologies for vaccine development. During this meeting, the committee will discuss the ways in which lessons from the clinical development of the COVID-19 vaccine can be leveraged to improve influenza vaccine research and development. Speakers will address topics such as best practices in clinical vaccine research, lessons from COVID-19, innovative trial design approaches and R&D capacity in various settings. These discussions will also consider feasibility in terms of policy and regulatory approval mechanisms.

Additional Information

Is it a Closed Session event?

Partially Closed

The following committee members were present at the closed sessions of the event

• Enriqueta Bond
• Kanta Subbarao
• Maria Elena Bottazzi
• Annette Fox
• Florian Krammer
• Grace Lee
• Milagritos Tapia
• Joshua Sharfstein

The following topics were discussed in the closed sessions:

• Review of Report Timeline and agendas for upcoming meetings
• Discussion of key findings, conclusions, recommendations and gaps

The following materials (written documents) were made available to the committee in the closed sessions:

Briefing Book

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Overview of Vaccine Science: Establishing Priorities to Improve Influenza Vaccines

April 15, 2021

3:00 PM - 6:00 PM (ET)

Past

Agenda

Download the Agenda

About

For their third meeting, the committee will continue its discussion of the basic and translational science that underpins the research and development of influenza vaccines. This session will center on identifying priorities for influenza vaccine research and development as it pertains to seasonal, pandemic and universal influenza. The session will apply previous discussions of translational science and emerging technologies to fit a global context.

Additional Information

Is it a Closed Session event?

Partially Closed

The following committee members were present at the closed sessions of the event

Members in Attendance
1. Enriqueta Bond
2. Kanta Subbarao
3. Maria Elena Bottazzi
4. Rebecca Cox
5. Annette Fox
6. Florian Krammer
7. Grace M. Lee
8. Joshua Sharfstein
9. Milagritos Tapia

The following topics were discussed in the closed sessions:

• Review of Previous Meeting Discussions
• Discussion of Presentations including key findings, conclusions, recommendations, and gaps

Date of posting of Closed Session Summary:

April 21, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Overview of Vaccine Science: Existing Evidence and Lessons from COVID-19

March 30, 2021

3:00 PM - 6:00 PM (ET)

Past

Agenda

Download the Agenda

About

The committee will discuss the basic and translational science that underpins influenza vaccine research and development. Topics to be discussed include an overview of vaccine platforms, the effects of repeat immunization, and a summary of progress being made towards a universal influenza vaccine. The experts will also focus their discussion on lessons learned from COVID-19 and apply these principles to influenza vaccine development processes.

Additional Information

Is it a Closed Session event?

Partially Closed

The following committee members were present at the closed sessions of the event

1. Enriqueta Bond
2. Kanta Subbarao
3. Florian Krammer
4. Grace Lee
5. Milagritos Tapia
6. Annette Fox
7. Maria Elena Bottazzi
8. Joshua Sharfstein

The following topics were discussed in the closed sessions:

• Planning Proposed Meeting structure
• Discussion of Key Finding, Conclusions, Recommendations, and Gaps

The following materials (written documents) were made available to the committee in the closed sessions:

Briefing Book

Date of posting of Closed Session Summary:

April 01, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Introduction to the Vaccine Research and Development Landscape

March 8 - 10, 2021

Past

Agenda

Download the Agenda

About

The committee will examine the technological and scientific advances achieved during the global response to COVID-19 and other outbreaks in vaccine research, development, and manufacturing. This includes analyzing the use of platform technologies and recommended strategies to harness the science, technology, policy, and practice to improve global influenza pandemic preparedness and response. During this meeting, the committee will review the project task and its background, and work to define an operational framework to complete its mandate.

Additional Information

Is it a Closed Session event?

Partially Closed

The following committee members were present at the closed sessions of the event

3/8/21
• Florian Krammer
• Kanta Subbarao
• John Martin
• Grace Lee
• Milagritos Tapia
• Annette Fox
• Maria Elena Bottazzi
• Joshua Sharfstein
• Enriqueta Bond

3/10/21 – Morning Session
• Florian Krammer
• Kanta Subbarao
• John Martin
• Grace Lee
• Milagritos Tapia
• Maria Elena Bottazzi
• Rebecca Cox
• Joshua Sharfstein
• Enriqueta Bond

3/10/21 – Afternoon Session
• Florian Krammer
• Kanta Subbarao
• John Martin
• Grace Lee
• Milagritos Tapia
• Annette Fox
• Maria Elena Bottazzi
• Rebecca Cox
• Joshua Sharfstein
• Enriqueta Bond

The following topics were discussed in the closed sessions:

3/8/21
• Introductions
• Conflict of Interest Discussion
• Orientation to the Consensus Study
• Discussion of Committee’s Charge

3/10/21
• Discussion of Statement of Task
• Recap of Speaker Session
• Define Working Framework
• Discussion of Statement of Task
• Setting Goals for Meeting 2

Date of posting of Closed Session Summary:

March 12, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Closed

Influenza Vaccine Research and Development Recommendations Part Three

August 2, 2021

8:00 AM - 11:00 AM (ET)

Past

About

On August 2, 2021, the Committee on Vaccine Research and Development Recommendations for Advancing Pandemic and Seasonal Influenza and Response met virtually for a closed session to discuss report findings.

Additional Information

Is it a Closed Session event?

Institution Closed

The following committee members were present at the closed sessions of the event

Enriqueta C. Bond
Kanta Subbarao
Maria Elena Bottazzi
Annette Fox
Florian Krammer
Milagritos Tapia
Joshua Sharfstein

The following topics were discussed in the closed sessions:

Review of conclusions and recommendations.

The following materials (written documents) were made available to the committee in the closed sessions:

Draft Report

Date of posting of Closed Session Summary:

August 04, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Closed

Influenza Vaccine Research and Development Recommendations Part Two

July 12, 2021

7:00 AM - 10:00 AM (ET)

Past

About

On July 12, 2021, the Committee on Vaccine Research and Development Recommendations for Advancing Pandemic and Seasonal Influenza and Response met virtually for a closed session to discuss report findings.

Additional Information

Is it a Closed Session event?

Institution Closed

The following committee members were present at the closed sessions of the event

• Enriqueta Bond
• Kanta Subbarao
• Maria Elena Bottazzi
• Rebecca Cox
• Annette Fox
• Florian Krammer
• Grace Lee
• Joshua Sharfstein
• Milagritos Tapia

The following topics were discussed in the closed sessions:

Review of report findings, conclusions, and recommendations.

Date of posting of Closed Session Summary:

July 16, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Closed

Influenza Vaccine Research and Development Recommendations Part One

June 22, 2021

3:00 PM - 6:00 PM (ET)

Past

About

On June 22, 2021, the Committee on Vaccine Research and Development Recommendations for Advancing Pandemic and Seasonal Influenza and Response met virtually for a closed session to discuss report findings, recommendations, and conclusions.

Additional Information

Is it a Closed Session event?

Institution Closed

The following committee members were present at the closed sessions of the event

Enriqueta Bond
Kanta Subbarao
Maria Elena Bottazzi
Annette Fox
Florian Krammer
Grace Lee
Joshua Sharfstein
Milagritos Tapia

The following topics were discussed in the closed sessions:

Review of Findings, Conclusions, and Recommendations

Date of posting of Closed Session Summary:

June 28, 2021

Contact

Contact us

FluPreparednessStudyRD@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Log In

Sign in to access your saved publications, downloads, and email preferences.

Former MyNAP users: You'll need to reset your password on your first login to MyAcademies. Click "Forgot password" below to receive a reset link via email. Having trouble? Visit our FAQ page to contact support.

Members of the National Academy of Sciences, National Academy of Engineering, or National Academy of Medicine should log in through their respective Academy portals.

Email (required)
Password (required)

Don't have an account?

Register

Email (required)
New password (required)
Retype password (required) Password must be at least 8 characters
I accept the terms of use
terms of use

Thank You

Thank you for creating a MyAcademies account!

Enjoy free access to thousands of National Academies' publications, a 10% discount off every purchase, and build your personal library.

Forgot Password

Enter the email address for your MyAcademies (formerly MyNAP) account to receive password reset instructions.

Reset Requested

We sent password reset instructions to your email . Follow the link in that email to create a new password. Didn't receive it? Check your spam folder or contact us for assistance.

Reset Password

New password (required)
Retype password (required) Password must be at least 8 characters

Reset Password

Your password has been reset.

Log In

Verify email

Verify Your Email Address

We sent a verification link to your email. Please check your inbox (and spam folder) and follow the link to verify your email address. If you did not receive the email, you can request a new verification link below

Subscribe

First Name
Last Name
Email (required)
I agree to receive emails from the National Academies (required)

We respect your privacy and will never share your information.

My Academies

Vaccine Research and Development Recommendations for Advancing Pandemic and Seasonal Influenza Preparedness and Response

Dropdown items

Regulatory Science of Influenza Vaccine Research and Development

Manufacturing Science of Influenza Vaccine Research and Development

Priorities for Clinical Development of Vaccines for Influenza Preparedness

Clinical Development of Vaccine Platforms for Influenza Preparedness

Overview of Vaccine Science: Establishing Priorities to Improve Influenza Vaccines

Overview of Vaccine Science: Existing Evidence and Lessons from COVID-19

Introduction to the Vaccine Research and Development Landscape

Influenza Vaccine Research and Development Recommendations Part Three

Influenza Vaccine Research and Development Recommendations Part Two

Influenza Vaccine Research and Development Recommendations Part One